Patents by Inventor Yun-Ping Zhou

Yun-Ping Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
    Patent number: 8268779
    Abstract: Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: September 18, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ranabir Sinha Roy, Elisabetta Bianchi, Antonello Pessi, Paolo Ingallinella, Donald J. Marsh, George J. Eiermann, Yingjun Mu, Yun-Ping Zhou
  • MICRORNA AS A BIOMARKER OF PANCREATIC ISLET BETA-CELL ENGAGEMENT
    Publication number: 20120034608
    Abstract: MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression and which play important roles in many cell types, including as described herein, the pancreatic ?-cell. Glucagon like peptide-1 (GLP-1), a hormone released from intestinal L-cells following meal intake, exerts pleiotropic effects on ?-cell function including raising intracellular cAMP levels and now represents an important therapy for type 2 diabetes. Expression of miR-132 and miR212 is upregulated by CREB protein in response increased cAMP levels in the cell; therefore, methods for detecting and evaluating ?-cell engagement by GLP-1 receptor agonists by monitoring miR-132 and miR-212 expression in a subject is described. The methods herein are particularly useful in the context of longitudinal clinical trials, such as those designed for testing the durability of any single or combination therapy in type 2 diabetes populations.
    Type: Application
    Filed: April 5, 2010
    Publication date: February 9, 2012
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yun-Ping Zhou, Andrew D. Howard, Jin Shang
  • PHARMACEUTICAL COMPOSITION COMPRISING OXYNTOMODULIN DERIVATIVES AND A METHOD FOR REDUCING BODY WEIGHT USING THE COMPOSITION
    Publication number: 20110183902
    Abstract: Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.
    Type: Application
    Filed: March 21, 2011
    Publication date: July 28, 2011
    Applicants: Merck Sharp & Dohme Corp., Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Ranabir Sinha Roy, Elisabetta Bianchi, Antonello Pessi, Paolo Ingallinella, Donald J. Marsh, George J. Eiermann, Yingjun Mu, Yun-Ping Zhou
  • PANCREATIC BETA-CELL MASS BIOMARKER
    Publication number: 20110123443
    Abstract: A biomarker for pancreatic beta-cell mass comprising measuring the levels of CFC1 in the serum of a subject is described. The biomarker provides a noninvasive means for measuring pancreatic beta cell mass that is particularly useful for monitoring the efficacy of treatments for metabolic disorders such as Type I or Type II diabetes, including pancreatic islet cell transplantations.
    Type: Application
    Filed: April 10, 2009
    Publication date: May 26, 2011
    Applicant: MERCK & CO., INC.
    Inventors: Yun-Ping Zhou, Andrew Howard, Nancy Thornberry
  • Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
    Patent number: 7928058
    Abstract: Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: April 19, 2011
    Assignees: Merck Sharp & Dohme Corp., Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Ranabir Sinha Roy, Elisabetta Bianchi, Antonello Pessi, Paolo Ingallinella, Donald J. Marsh, George J. Eiermann, Yingjun Mu, Yun-Ping Zhou
  • Diagnosis and treatment of type 2 diabetes and other disorders
    Patent number: 7879859
    Abstract: The present application features the use of the somatostatin subtype 3 receptor (SST3) as a target for affecting insulin secretion and for diagnosing diabetes related disorders. Glucose stimulated insulin secretion was found to be stimulated by knocking down expression of SST3 and through the use of a SST3 selective antagonist.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: February 1, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yun-Ping Zhou, Jing Li, Weizhen Wu, Jin Shang, John R. Thompson, Nancy A. Thornberry
  • OXGR1 AGONISTS FOR USE IN THERAPIES FOR METABOLIC DISORDERS
    Publication number: 20100143383
    Abstract: Methods for identifying OXGR1 modulator useful for the treatment of diabetes and conditions associated with diabetes are provided. Further provided are methods for treating diabetes and conditions associated with diabetes with an OXGR1 agonist.
    Type: Application
    Filed: October 29, 2009
    Publication date: June 10, 2010
    Inventors: Andrew D. Howard, Jing Li, Yun-Ping Zhou
  • Oxyntomodulin Derivatives
    Publication number: 20100144617
    Abstract: Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.
    Type: Application
    Filed: February 16, 2007
    Publication date: June 10, 2010
    Inventors: Ranabir Sinha Roy, Elisabetta Bianchi, Antonello Pessi, Paolo Ingallinella, Donald J. Marsh, George J. Eiermann, Yingjun Mu, Yun-Ping Zhou
  • Diagnosis and treatment of type 2 diabetes and other disorders
    Publication number: 20090131451
    Abstract: The present application features the use of the somatostatin subtype 3 receptor (SST3) as a target for affecting insulin secretion and for diagnosing diabetes related disorders. Glucose stimulated insulin secretion was found to be stimulated by knocking down expression of SST3 and through the use of a SST3 selective antagonist.
    Type: Application
    Filed: November 17, 2006
    Publication date: May 21, 2009
    Inventors: Yun-Ping Zhou, Jing Li, Weizhen Wu, Jin Shang, John R. Thompson, Nancy A. Thornberry
  • Compositions and methods of using apoptosis signaling kinase related kinase (ASKRK)
    Publication number: 20080248010
    Abstract: The invention provides apoptosis signaling kinase related kinase (ASKRK) nucleic acid and polypeptide sequences and methods of using such sequences to identify modulators of ASKRK. Such modulators can be used for the treatment of diabetes or for delaying the onset of diabetes. The invention also provides methods of diagnosing diabetes or pre-diabetes and methods of making a prognosis based on the detection of ASKRK nucleic acids and proteins.
    Type: Application
    Filed: March 17, 2008
    Publication date: October 9, 2008
    Applicant: Metabolex, Inc.
    Inventors: Jeffrey D. Johnson, Yun-Ping Zhou, Kimberly Marlen
  • Compositions and methods of using apoptosis signaling kinase related kinase (ASKRK)
    Patent number: 7344844
    Abstract: The invention provides apoptosis signaling kinase related kinase (ASKRK) nucleic acid and polypeptide sequences and methods of using such sequences to identify modulators of ASKRK. Such modulators can be used for the treatment of diabetes or for delaying the onset of diabetes. The invention also provides methods of diagnosing diabetes or pre-diabetes and methods of making a prognosis based on the detection of ASKRK nucleic acids and proteins.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: March 18, 2008
    Assignee: Metabolex, Inc.
    Inventors: Jeffrey D. Johnson, Yun-Ping Zhou, Kimberly Marlen
  • Methods and Reagents for Diagnosis and Treatment of Diabetes
    Publication number: 20080064857
    Abstract: The invention relates to methods and reagents for diagnosing and treating diabetes.
    Type: Application
    Filed: September 20, 2007
    Publication date: March 13, 2008
    Applicant: Metabolex, Inc.
    Inventors: Jeffrey JOHNSON, John Blume, John Palma, Yun-Ping Zhou
  • Methods and reagents for diagnosis and treatment of diabetes
    Patent number: 7294698
    Abstract: The invention relates to methods and reagents for diagnosing and treating diabetes.
    Type: Grant
    Filed: November 1, 2006
    Date of Patent: November 13, 2007
    Assignee: Metabolex, Inc.
    Inventors: Jeffrey D Johnson, John E. Blume, John F. Palma, Yun-Ping Zhou
  • Methods and reagents for diagnosis and treatment of diabetes
    Publication number: 20070055050
    Abstract: The invention relates to methods and reagents for diagnosing and treating diabetes.
    Type: Application
    Filed: November 1, 2006
    Publication date: March 8, 2007
    Applicant: Metabolex, Inc.
    Inventors: Jeffrey Johnson, John Blume, John Palma, Yun-Ping Zhou
  • Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-TRP
    Publication number: 20070031897
    Abstract: Expression of beta-TRP is enriched in islet cells. Introduction of expression cassettes encoding beta-TRP into diabetic islet cells improved glucose-stimulated insulin production.
    Type: Application
    Filed: June 9, 2006
    Publication date: February 8, 2007
    Applicant: Metabolex, Inc.
    Inventors: Jeffrey Johnson, Yun-Ping Zhou
  • Methods and reagents for diagnosis and treatment of diabetes
    Patent number: 7144985
    Abstract: The invention relates to methods of determining islet cell activity by detecting the level of Archipelin or a fragment thereof and comparing the level to a baseline level or range associated with a known islet cell activity. Such methods are useful in diagnosing and studying the development of diabetes.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: December 5, 2006
    Assignee: Metabolex, Inc.
    Inventors: Jeffrey D. Johnson, John E. Blume, John F. Palma, Yun-Ping Zhou
  • Compositions and methods of using apoptosis signaling kinase related kinase (ASKRK)
    Publication number: 20060252100
    Abstract: The invention provides apoptosis signaling kinase related kinase (ASKRK) nucleic acid and polypeptide sequences and methods of using such sequences to identify modulators of ASKRK. Such modulators can be used for the treatment of diabetes or for delaying the onset of diabetes. The invention also provides methods of diagnosing diabetes or pre-diabetes and methods of making a prognosis based on the detection of ASKRK nucleic acids and proteins.
    Type: Application
    Filed: July 17, 2006
    Publication date: November 9, 2006
    Applicant: Metabolex, Inc.
    Inventors: Jeffrey Johnson, Yun-Ping Zhou, Kimberly Marlen
  • Methods of treatment of type 2 diabetes
    Publication number: 20060234276
    Abstract: The present invention relates generally to the field of diabetes. More particularly, it concerns the identification of genes responsible for NIDDM1 for use in diagnostic and therapeutic applications. The present invention demonstrates that the NIDDM1 locus is, in fact, the calpain 10 gene. The invention further relates to the discovery that analysis of mutations in calpain genes and gene products can be diagnostic for type 2 diabetes. The invention also contemplates methods of treating diabetes in view of the fact that calpain mutations can cause diabetes. Further, the invention relates to novel polynucleotides of the NIDDM1 locus and polypeptides encoded by such polynucleotides.
    Type: Application
    Filed: March 30, 2006
    Publication date: October 19, 2006
    Inventors: Kenneth Polonsky, Yukio Horikawa, Naohisa Oda, Nancy Cox, Seamus Sreenan, Yun-Ping Zhou, Kenichi Otani, Craig Hanis, Graeme Bell
  • Compositions and methods of using apoptosis signaling kinase related kinase (ASKRK)
    Patent number: 7109021
    Abstract: The invention provides apoptosis signaling kinase related kinase (ASKRK) nucleic acid and polypeptide sequences and methods of using such sequences to identify modulators of ASKRK. Such modulators can be used for the treatment of diabetes or for delaying the onset of diabetes. The invention also provides methods of diagnosing diabetes or pre-diabetes and methods of making a prognosis based on the detection of ASKRK nucleic acids and proteins.
    Type: Grant
    Filed: November 3, 2004
    Date of Patent: September 19, 2006
    Assignee: Metabolex, Inc.
    Inventors: Jeffrey D. Johnson, Yun-Ping Zhou, Kimberly Marlen
  • Compositions and methods of using apoptosis signaling kinase related kinase (ASKRK)
    Patent number: RE40624
    Abstract: The invention provides apoptosis signaling kinase related kinase (ASKRK) nucleic acid and polypeptide sequences and methods of using such sequences to identify modulators of ASKRK. Such modulators can be used for the treatment of diabetes or for delaying the onset of diabetes. The invention also provides methods of diagnosing diabetes or pre-diabetes and methods of making a prognosis based on the detection of ASKRK nucleic acids and proteins.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: January 20, 2009
    Assignee: Metabolex, Inc.
    Inventors: Jeffrey D. Johnson, Yun-Ping Zhou, Kimberly Marlen